Taya V. Glotzer
A5070161365- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
- Long-Term Effects of COVID-19
- Acute Ischemic Stroke Management
- Heart Rate Variability and Autonomic Control
- COVID-19 Clinical Research Studies
- ECG Monitoring and Analysis
- Venous Thromboembolism Diagnosis and Management
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 diagnosis using AI
- Cardiomyopathy and Myosin Studies
- Cardiac Imaging and Diagnostics
- Cardiovascular Syncope and Autonomic Disorders
- Blood Pressure and Hypertension Studies
- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Healthcare Technology and Patient Monitoring
- SARS-CoV-2 and COVID-19 Research
- Phonocardiography and Auscultation Techniques
- Non-Invasive Vital Sign Monitoring
- Lymphoma Diagnosis and Treatment
- E-commerce and Technology Innovations
Hackensack University Medical Center
2016-2025
Center for Discovery
2021-2025
Hackensack Meridian Health
2018-2025
White Plains Hospital
2023
Heart Rhythm Society
2023
Stroke Association
2021-2023
Laboratoire Lorrain de Recherche en Informatique et ses Applications
2023
Rutgers, The State University of New Jersey
2018-2020
Rutgers New Jersey Medical School
2018
Shanghai Institute of Hypertension
2017
Background— It is unknown if brief episodes of device-detected atrial fibrillation (AF) increase thromboembolic event (TE) risk. Methods and Results— TRENDS was a prospective, observational study enrolling patients with ≥1 stroke risk factor (heart failure, hypertension, age ≥65 years, diabetes, or prior TE) receiving pacemakers defibrillators that monitor tachycardia (AT)/AF burden (defined as the longest total AT/AF duration on any given day during 30-day period). This time-varying...
Background— Some current pacing systems can automatically detect and record atrial tachyarrhythmias that may be asymptomatic. We prospectively studied a 312-patient (pt) subgroup of MOST (MOde Selection Trial), 2010-patient, 6-year randomized trial DDDR versus VVIR in sinus node dysfunction (SND). The purpose the study was to correlate high rate events (AHREs) detected by pacemaker diagnostics with clinical outcomes. Methods Results— Pacemakers were programmed log an AHRE when >220 bpm...
The aim of this study was to assess the association between maximum daily atrial fibrillation (AF) burden and risk ischaemic stroke. Cardiac implanted electronic devices (CIEDs) enhance detection AF, providing a comprehensive measure AF burden. A pooled analysis individual patient data from five prospective studies performed. Patients without permanent previously with CIEDs, were included if they had at least 3 months follow-up. total 10 016 patients (median age 70 years) met these criteria....
Patients with ischemic stroke attributed to large- or small-vessel disease are not considered at high risk for atrial fibrillation (AF), and the AF incidence rate in this population is unknown.To determine whether long-term cardiac monitoring more effective than usual care detection patients through 12 months of follow-up.The STROKE-AF trial was a randomized (1:1), multicenter (33 sites US) clinical that enrolled 496 between April 2016 July 2019, primary end point follow-up August 2020....
Abstract Remote monitoring is beneficial for the management of patients with cardiovascular implantable electronic devices by impacting morbidity and mortality. With increasing numbers using remote monitoring, keeping up higher volume transmissions creates challenges device clinic staff. This international multidisciplinary document intended to guide cardiac electrophysiologists, allied professionals, hospital administrators in managing clinics. includes guidance staffing, appropriate...
Evidence of atrial tachycardia/atrial fibrillation (AT/AF) is often sought in patients with ischemic stroke or transient attack. We studied previous thromboembolic events (TE) who were implanted devices capable continuous arrhythmia monitoring to comprehensively quantify the incidence and duration newly detected AT/AF.This study represents a subgroup analysis TRENDS trial, which included clinical indications for pacemakers defibrillators >or=1 risk factors (heart failure, hypertension, age...
To develop quality indicators (QIs) that may be used to evaluate the of care and outcomes for adults with atrial fibrillation (AF).We followed ESC methodology QI development. This involved (i) identification domains AF diagnosis management (by a group experts including members Clinical Practice Guidelines Task Force AF); (ii) construction candidate QIs (including systematic review literature); (iii) selection final set (using modified Delphi method). Six were identified: Patient assessment...
Abstract Aims Atrial tachyarrhythmia recurrence ≥30 s remains the primary endpoint of clinical trials; however, this definition has not been correlated with outcomes or pathophysiological processes. This study sought to determine atrial duration and burden associated meaningful outcomes. Methods results The time every episode recorded on implantable cardiac monitor were evaluated. Healthcare utilization quality life in year following ablation prospectively collected. Three hundred forty-six...
Cardiac physiologic pacing (CPP), encompassing cardiac resynchronization therapy (CRT) and conduction system (CSP), has emerged as a strategy that may mitigate or prevent the development of heart failure (HF) in patients with ventricular dyssynchrony pacing-induced cardiomyopathy. This clinical practice guideline is intended to provide guidance on indications for CRT HF CPP pacemaker HF, patient selection, pre-procedure evaluation preparation, implant procedure management, follow-up...